Member Exclusive

New funding will support development of personalized cell therapies for compromised patient populations

A Biomedical Catalyst Primer Award will fund research into low transfection efficient in patients with already highly compromised cell populations.

Go to the profile of Freya Leask
Oct 10, 2017

Please sign in or register for FREE

Register to RegMedNet

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.


No comments yet.